Metropolitan Life Insurance Company (MetLife)’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-17,400	Closed	-$160K	–	2647
2017 Q1	$160K	Buy	+17,400	New	+$153K	﹤0.01%	2381
2016 Q4	–	Sell	-14,742	Closed	-$169K	–	2697
2016 Q3	$169K	Buy	14,742 +581	+4%	+$6.76K	﹤0.01%	2440
2016 Q2	$174K	Sell	14,161 -798	-5%	-$9.68K	﹤0.01%	2420
2016 Q1	$151K	Buy	14,959 +90	+0.6%	+$1.06K	﹤0.01%	2342
2015 Q4	$335K	Buy	14,869 +4,035	+37%	+$82.7K	﹤0.01%	1896
2015 Q3	$180K	Hold	10,834	–	–	﹤0.01%	2359
2015 Q2	$244K	Buy	10,834 +524	+5%	+$12.9K	﹤0.01%	2266
2015 Q1	$266K	Hold	10,310	–	–	﹤0.01%	1902
2014 Q4	$224K	Hold	10,310	–	–	﹤0.01%	2338
2014 Q3	$195K	Buy	10,310 +40	+0.4%	+$804	﹤0.01%	2387
2014 Q2	$239K	Buy	+10,270	New	+$254K	﹤0.01%	2384

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OMED Position: Q2 2017 in Review

Metropolitan Life Insurance Company (MetLife) sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 17,400 shares — an estimated $160K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OMED in Q2 2014 and held it in 11 quarters. The position peaked at $335K in Q4 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

Metropolitan Life Insurance Company (MetLife) reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 17,400 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $160K.
Metropolitan Life Insurance Company (MetLife) first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s OncoMed Pharmaceuticals, Inc. position peaked at $335K in Q4 2015.
68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2017, filed 14 Aug 2017.